Print

AVEG 032

A Phase I Trial to Evaluate the HIV-1 SF-2 Recombinant p24 Subunit Vaccine Administered as a Novel Boost in "Prime Boost" Vaccination Regiments with ALVAC-HIV vCP205 (PMC) and HIV-1 SF-2 rgp120 in MF59 (Chiron)

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) August 05, 1999
ALVAC-HIV MN120TMG strain (vCP205),rgp120/HIV-1 SF-2 Canarypox Env gp120, TM gp41, gag, protease B MN/LAI; Protein Env gp120 B SF-2
ALVAC-HIV MN120TMG strain (vCP205) Viral Vector - Pox
rgp120/HIV-1 SF-2 Protein
MF59
USA 64
NCT00000946
https://clinicaltrials.gov/show/NCT00000946